RxDoctor Payments Data

Dawn Stoecker-Simon, MD

Internal Medicine · Houston, TXNPI 1588641062

Payments from drug & device makers

$2,460in general payments, 2019–2025

Across 134 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$240
  • Radius Health, Inc.$191
  • Dexcom, Inc.$147
  • AstraZeneca$139
  • AbbVie$127
  • Corcept Therapeutics$121
  • plus $1K from 36 others

What the payments were for

  • Food & beverage$2,43399%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,460 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$193,656
Medicare patients
526
Services billed
12,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$135,288
EliquisApixaban128$117,586
MounjaroTirzepatide41$52,141
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$36,783
RybelsusSemaglutide29$36,325
XareltoRivaroxaban23$26,575
MyrbetriqMirabegron32$25,561
Repatha SureclickEvolocumab29$22,491
JardianceEmpagliflozin14$20,905
SynthroidLevothyroxine Sodium200$16,080
Breo ElliptaFluticasone/Vilanterol41$15,645
TrulicityDulaglutide15$15,384
JanuviaSitagliptin Phosphate18$13,756
GemtesaVibegron12$12,617
Lagevrio (Eua)Molnupiravir15$9,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$240$171,613137 claims
PfizerEliquis, Premarin, Paxlovid$94$132,648233 claims
Lilly USA, LLCMounjaro, Trulicity$82$67,52556 claims
GSKTrelegy Ellipta, Breo Ellipta$91$52,42879 claims
Johnson & JohnsonXarelto$41$26,57523 claims
Astellas Pharma US IncMyrbetriq$77$25,56132 claims
MerckJanuvia, Lagevrio (Eua)$44$23,67433 claims
Boehringer IngelheimJardiance$15$20,90514 claims
AbbVieSynthroid, Armour Thyroid$127$18,443224 claims
Sumitomo Pharma America, Inc.Gemtesa$25$12,61712 claims
AstraZenecaSymbicort$139$6,04214 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$4,499444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →